Pyrazolone Compounds as Promising Anticancer Agents for Colorectal Cancer: Synthesis, Antiproliferative Activity, and Mechanistic Insights
ChemMedChem · 2026
DOI: 10.1002/cmdc.202500864 ↗Kurz gefasst
Fachartikel in der Zeitschrift ChemMedChem, 2026. Verfasst von Ali Gholamian Moghaddam und 6 weiteren Autor:innen. Beteiligte Einrichtung: School of Sciences, College of Arts, Education and Sciences, University of Louisiana at Monroe, Monroe, Louisiana, USA. Hauptthemen laut MEDLINE: Antineoplastic Agents, Colorectal Neoplasms, Pyrazolones. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 46 Literaturangaben. Gefördert von: IDeA Networks of Biomedical Research Excellence, Louisiana Biomedical Research Network, Louisiana Cancer Research Center.
Abstract (Originalsprache)
Colorectal cancer (CRC) remains a major global health challenge, with current therapeutic options often limited by drug resistance and adverse effects. Small molecules provide distinct advantages, including oral bioavailability, cost‐effectiveness, and the ability to target intracellular pathways critical for tumor progression. In this study, we designed and synthesized a new series of pyrazolone derivatives with varied substitution patterns using microwave‐assisted methods and evaluated their antiproliferative activity against CRC cell lines (HCT‐116 and WiDr). Among these, PL‐13 emerged as a potent and selective candidate, exhibiting strong cytotoxicity toward cancer cells while sparing noncancerous CRL‐1459 colon cells. Functional assays, including colony formation and wound healing, confirmed its ability to inhibit cell proliferation and migration. Western blot analyses demonstrated that PL‐13 induces apoptosis via the intrinsic mitochondrial pathway, as evidenced by increased levels of cleaved caspase‐9 and PARP, and modulates LC3A/B expression, suggesting involvement of autophagy. Kinome profiling revealed selective binding of PL‐13 to FLT3, which was validated by an IC 50 value of 8.2 μM. Molecular docking further supported these findings, showing favorable binding energy (–7.98 kcal/mol) compared to regorafenib (–7.13 kcal/mol). Collectively, these results highlight PL‐13 as a promising lead compound for further optimization toward CRC therapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- School of Sciences, College of Arts, Education and Sciences, University of Louisiana at Monroe, Monroe, Louisiana, USA.
- Department of Pathobiological Sciences, School of Veterinary Medicine, Louisiana State University, Baton Rouge, Louisiana, USA.
- School of Basic Pharmaceutical and Toxicological Sciences, College of Pharmacy, University of Louisiana at Monroe, Monroe, Louisiana, USA.
ORCID-Profile: Siva Murru
Förderung
- IDeA Networks of Biomedical Research Excellence
- Louisiana Biomedical Research Network
- Louisiana Cancer Research Center
- Louisiana Board of Regents Support Fund
Zitieren
APA
Gholamian Moghaddam, A., Siriki, A., Majumder, D., Elsayed, H. E., Ebrahim, H. Y., Sayed, K. E., & Murru, S. (2026). Pyrazolone Compounds as Promising Anticancer Agents for Colorectal Cancer: Synthesis, Antiproliferative Activity, and Mechanistic Insights. ChemMedChem. https://doi.org/10.1002/cmdc.202500864
Vancouver
Gholamian Moghaddam A, Siriki A, Majumder D, Elsayed HE, Ebrahim HY, Sayed KE, et al. Pyrazolone Compounds as Promising Anticancer Agents for Colorectal Cancer: Synthesis, Antiproliferative Activity, and Mechanistic Insights. ChemMedChem. 2026. doi:10.1002/cmdc.202500864
BibTeX
@article{GholamianMoghaddam2026,
author = {Gholamian Moghaddam, Ali and Siriki, Atchimnaidu and Majumder, Debajyoti and Elsayed, Heba E and Ebrahim, Hassan Y and Sayed, Khalid El and Murru, Siva},
title = {Pyrazolone Compounds as Promising Anticancer Agents for Colorectal Cancer: Synthesis, Antiproliferative Activity, and Mechanistic Insights},
journal = {ChemMedChem},
year = {2026},
doi = {10.1002/cmdc.202500864}
}
EUVIMED